ANSLY:OTC-Ansell Limited (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC

Last Closing Price

USD 75.95

Change

+1.44 (+1.93)%

Market Cap

USD 2.42B

Volume

720.00

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Ansell Limited (ANSLY) Stock Analysis:
Based on the Ansell Limited stock forecasts from 0 analysts, the average analyst target price for Ansell Limited is not available over the next 12 months. Ansell Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Ansell Limited is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Ansell Limited’s stock price was USD 75.95. Ansell Limited’s stock price has changed by +3.60% over the past week, +1.59% over the past month and -40.42% over the last year.

No recent analyst target price found for Ansell Limited
No recent average analyst rating found for Ansell Limited

About

Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets s ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SAUHF Straumann Holding AG

+4.24 (+3.62%)

USD218.20B 520.72 34.00
ESLOF EssilorLuxottica Société ano..

-5.62 (-3.57%)

USD69.74B 45.58 16.28
ESLOY EssilorLuxottica Société ano..

+0.13 (+0.17%)

USD68.42B 45.06 16.28
HOCPF HOYA Corporation

+0.34 (+0.35%)

USD35.15B 29.65 0.13
HOCPY HOYA Corporation

+0.31 (+0.32%)

USD34.14B 29.04 0.13
RSMDF ResMed Inc

N/A

USD32.18B 16.61 24.35
SDMHF Sartorius Stedim Biotech S.A

N/A

USD30.38B 48.80 29.23
OCPNF Olympus Corporation

-0.85 (-4.00%)

USD27.05B 36.02 0.13
CLPBF Coloplast A/S

-3.18 (-2.62%)

USD26.97B 37.36 4.13
CLPBY Coloplast A/S

-0.09 (-0.74%)

USD25.69B 37.78 4.13

ETFs Containing ANSLY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.24% 80% B- 51% F
Dividend Return 1.10% 67% D+ 26% F
Total Return -13.14% 74% C 49% F
Trailing 12 Months  
Capital Gain -40.42% 45% F 37% F
Dividend Return 2.13% 72% C- 28% F
Total Return -38.29% 47% F 38% F
Trailing 5 Years  
Capital Gain 7.41% 47% F 60% D-
Dividend Return 12.49% 60% D- 44% F
Total Return 19.90% 49% F 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 9.75% 17% F 48% F
Dividend Return 1.98% 59% F 46% F
Total Return 11.73% 20% F 47% F
Risk Return Profile  
Volatility (Standard Deviation) 26.85% 83% B 72% C-
Risk Adjusted Return 43.69% 43% F 70% C-
Market Capitalization 2.42B 57% F 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 11.04 86% B 55% F
Price/Book Ratio 1.57 79% C+ 49% F
Price / Cash Flow Ratio 13.99 35% F 12% F
EV/EBITDA 7.76 48% F 34% F
Management Effectiveness  
Return on Equity 14.38% 64% D 76% C
Return on Invested Capital 10.86% 56% F 71% C-
Return on Assets 7.22% 71% C- 88% B+
Debt to Equity Ratio 29.12% 43% F 48% F
Technical Ratios  
Dividend Yield 3.71% 93% A 52% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.42 60% D- 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector